Multidisciplinary Association for Psychedelic Studies

NeonMind Goes Public Psychedelics biotech company NeonMind debuted on the Canadian Securities Exchange (CSE) Monday under the symbol ‘NEON.’ NeonMind CEO Penny White discussed the highly anticipated — oversubscribed — initial public offering (IPO) on the Jan. 7 edition...

While many 2020 memories will be gladly left behind, that's not necessarily the case for psychedelics. There was unprecedented renaissance as psychedelic compounds, and their potential to treat mental health conditions, became one of the centerpieces of this year’s public...

Numinus and MAPS Collaborate to Study MDMA in Canada Numinus Wellness (TSXV: NUMI) and the MAPS Public Benefit Corporation have joined forces to bring MDMA-assisted psychotherapy through clinical trials for approval in Canada. The pair will first seek permission to perform a single-arm, open-label...

Psychedelics and biotech company ATAI Life Sciences announced on Monday the launch of a new subsidiary that will focus on the development of MDMA derivatives for the treatment of post-traumatic stress disorder and other indications. EmpathBio will be a wholly owned subsidiary of ATAI, led by CEO...

MAPS Gets $30M In Funds To Conclude MDMA Research The Multidisciplinary Association for Psychedelic Studies recently completed a fundraising of $30 million. The funds will help MAPS finish the NGO’s ongoing research for MDMA-assisted psychotherapy in the treatment of post-...

After 34 years of work, the Multidisciplinary Association for Psychedelic Studies (MAPS) is steps away from achieving FDA approval for MDMA-assisted psychotherapy in the treatment of post-traumatic stress disorder.  This would be the first time in history a psychedelic substance is approved by...